Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study

The Lancet

Volumn 346, Issue 8990, 1995, Pages 1575-1582

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; NORETHISTERONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0029564931     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)91926-0     Document Type: Article

References (47)

1. Pulmonary embolism
2. Oral contraception and thromboembolic disease
3. Investigation of relation between use of oral contraceptives and thromboembolic disease
4. Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report
5. Thromboembolism and oral contraceptives: an epidemiologic case-control study
6. Postoperative thromboembohsm and the use of oral contraceptives
7. Oral contraceptives and thromboembolic disease
8. Oral contraceptive use in patients with thromboembolism following surgery trauma or infection
9. Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumours
10. Oral contraceptives, smoking and other factors in relation to risk of venous thromboembolic disease
11. Increased risk of thrombosis due to oral contraceptives: a further report
12. Venous thromboembolism in relation to oral contraceptive use
13. Risk factors for fatal venous thromboembolism in young women: a case control study
14. Oral contraceptives and non-fatal vascular disease: recent experience
15. Oral contraceptives and non-fatal vascular disease
16. Oral contraceptives and venous thromboembolism: findings in a large prospective study
17. Oral contraceptives, venous thrombosis and varicose veins
18. Trends in use of oral contraceptives in Britain
19. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism
20. Accuracy of clinical assessment of deep-vein thrombosis
21. Diagnosis of pulmonary embolism: a correlative study of the clinical, scan, and angiographic findings
22. Clinical factors and the risk of deep venous thrombosis
23. Simulation study of confounder-selection strategies
24. Oral contraceptive use and venous thromboembolism: absence of an effect of smoking
25. Oral contraceptives, blood clotting and thrombosis
26. Estrogen-containing oral contraceptive agents: a basis for their thrombogenicity
27. Female hormones and vascular disease: an epidemiological overview
28. Oral contraceptives and cardiovascular disease
29. Thromboembolic disease and the steroidal content or oral contraceptives: a report to the Committee on Safety of Drugs
30. Thrombosis with low-estrogen oral contraceptives
31. Oral glucose tolerance and the potency of contraceptive progestins
32. The varying effcts of progestins on lipid levels and cardiovascular disease
33. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
34. Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene
35. Serum levels of 3 keto-desogestrel and SHBG during 12 cycles of treatment with 30 micrograms ethinylestradiol and 150 micrograms desogestrel
36. Relative bioavailability of ethinyl estradiol from two different oral contraceptive formulations after single oral administration to 18 women in an intraindividual cross-over design
37. Protein binding of active ingredients and comparison of serum ethinyl estradiol, sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ethin yl estradiol (Femovan) or a combination of desogestrel/ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives
38. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
39. Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies
40. Value of the ventilation/perfusion scan in acute pulmonary embolism
41. Silverman DT, Mandel JS. Selection of controls in case-control studies
42. The Jephcott lecture 1989: an overview of the benefits and risks of combined oral contraceptives